Legal Representation
Attorney
Danielle Cohen, Esq.
USPTO Deadlines
Next Deadline
100 days remaining
NOA E-Mailed - SOU Required
Due Date
April 01, 2026
Extension Available
Until October 01, 2026
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 25, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 25, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 25, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 25, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 1, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 31, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 31, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 31, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 1, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 6, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 6, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 17, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 1, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 28, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 28, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 28, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 24, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 24, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 24, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 20, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 24, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Dec 16, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer featuring small molecules, biopharmaceuticals, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; Pharmaceutical preparations for the treatment of cancer for use in cellular therapies, gene therapies, N - 1 personalized drug therapies, and CAR T-cell therapy; Pharmaceutical preparations for the treatment of cancer derived from CRISPR-Cas9 and CAR T-Cell; Vaccine preparations; Antibodies for medical purposes, namely, monoclonal antibodies and bi-specific antibodies; Medical diagnostic reagents and diagnostic preparations for use in-vitro, in-vivo, cell-based assays, cell culture processes, laboratory-developed tests (LDTs), cell-based imagining, genomics, gene-based expression assays, proteomics, protein-based expression assays, immunohistochemistry (IHC), drug sensitivity and treatment diagnostics
Class 009
Downloadable medical computer software platforms containing diagnostic algorithms and decision-making computation to support screening, diagnosing, monitoring and treatment modalities of diseases; downloadable medical computer software platforms for aiding in decision-making in clinical and after-regulatory approval of therapeutics and diagnostics; downloadable medical computer software platforms for managing and maintaining pre-clinical trials, clinical trials and assessments of patient's tumors in their staging and treatment
Class 010
Medical apparatus for personalized medical therapeutics, namely, infusion and injection devices for administering therapeutic drugs of various types, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics, into the human body utilizing both in-vivo and in-vitro, gene or cellular therapy methods
Class 042
Medical research services in personalized medicine, patient treatment, therapeutics and diagnostics
Class 044
Biobanking services, namely, human and animal organ and tissue bank services; Medical digital pathology services for diagnostic or treatment purposes of human and animal tumors; Medical imaging services for cellular systems for the characterization of human and animal tumors
Classification
International Classes
005
009
010
042
044